Low‐dose diosbulbin‐B (DB) could inhibit properties of cancer stem cells and induce PD‐L1 depletion to activate NLRP3‐dependent pyroptosis, which effetely sensitize cisplatin‐resistant GC cells. Here, NLRP3 is linked to gastric cancer.